Ikena Oncology (IMA) - Periode bali modal bisnis
The R&D potential of ImageneBio Inc (IMA) is based on the creation of tumor metabolism inhibitors and targeted therapies, while the current standalone P/E ratio stands at -0.80. This chart of the current market value confirms the stability of development cycles, complemented by strict climate control during molecule transportation. The brand's high authority within the scientific community is driven by the efficacy of its methods for the precision destruction of resistant neoplasms.
Rincian analitis perusahaan ImageneBio Inc
- rega saham lan prakiraan rega para ahli:
- indikator kapitalisasi pasar:
- data kapitalisasi buku:
- data liabilitas lan likuiditas perusahaan:
Total Utang marang Modal ImageneBio Inc|IMA - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang modal Ikena Oncology, Inc.|IMA - Gunggung utang perusahaan|Utang-utang marang nilai buku ImageneBio Inc|IMA - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Ikena Oncology|Indikator likuiditas cepet ikenaoncology.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
IMA - Bathi resik|Proyeksi bathi mangsa ngarep ImageneBio Inc|IMA - Pangali P/E|Pangali forward rega marang bathi Ikena Oncology, Inc.|IMA - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan ImageneBio Inc|IMA - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajrone 12 wulan pungkasan Ikena Oncology|IMA - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan ikenaoncology.com|IMA - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep ImageneBio Inc
Ringkesan analisis perusahaan:IMA (ikenaoncology.com)
A conservative approach to the fundamental analysis of ImageneBio Inc (IMA) requires separating market speculation from the actual business value. The ratio of market capitalization to net income, reflected in the issuer's P/E history, measures the investment payback period, which is critical for a biotech company whose margins are temporarily constrained by high R&D costs and the pre-profit stage of clinical trials for oncology drugs.
Pesaing wigati
ARGX: Nilai perusahaan marang bathi resik|Pangali P/E BNTX|Periode bali modal bisnis ABIVAX|Rasio rega marang bathi ADMA Bio ADMA|PTGX - Koefisien rega marang bathi|IMVT - Rasio rega marang bathi|kiniksa.com (KNSA) - Koefisien rega marang bathi|GRFS (Grifols) - Koefisien rega marang bathi|Adaptive Biotech (ADPT) - Pangali P/E|Rasio rega marang bathi Celldex|Pangali rega marang bathi AUPH (Aurinia Corp)|Pangali P/E BCRX|VERA - Kapitalisasi marang bathi|Pangali P/E DNTH (Dianthus Therapeutics, Inc.)|Periode bali modal bisnis Pharvaris NV (PHVS)|ABCL - Rasio rega marang bathi|Tourmaline (TRML) - Koefisien rega marang bathi|PGEN: Pangali P/E|pharming.com (PHAR) - Pangali P/E|NKTR (Nektar Therapeutics Inc.) - Pangali P/E|UPB - Rasio kapitalisasi marang bathi resik|Pangali P/E ZBIO|IMNM - Kapitalisasi marang bathi|Rasio rega marang bathi Gossamer Bio, Inc. GOSS|KALV: Pangali rega marang bathi|Septerna - Pangali P/E|Kapitalisasi marang bathi Pieris Pharma|SVRA: Pangali P/E|RIGL (Rigel Corp) - Rasio rega marang bathi|ANAB (AnaptysBio, Inc.) - Pangali P/E|astriatx.com (ATXS) - Periode bali modal bisnis|Rasio rega marang bathi enGene (ENGN)|RAPT - Kapitalisasi marang bathi|Aerovate Therapeutics - Koefisien rega marang bathi|Nilai perusahaan marang bathi resik ACRS|Kyverna Therapeutics - Pangali P/E|Periode bali modal bisnis tizianalifesciences.com TLSA|Cabaletta Bio (CABA) - Rasio rega marang bathi|Pangali rega marang bathi VTYX|THTX (Theratechnologies Inc) - Pangali P/E|Koefisien rega marang bathi Avalo Therapeutics Inc (AVTX)|Pangali P/E ELDN|Periode bali modal bisnis agenusbio.com|Rasio rega marang bathi Climb Bio CLYM|ZURA - Koefisien rega marang bathi|aTyr - Pangali P/E|ADAG - Pangali P/E|shattucklabs.com (STTK) - Rasio rega marang bathi|Kapitalisasi marang bathi resik EQ (Equillium)|CNTB (Connect Biopharma Holdings) - Pangali P/E|IMUX: Nilai perusahaan marang bathi resik|Pangali P/E ATRA|Pangali P/E inflarx.de (IFRX)|Rasio rega marang bathi X4 Pharmaceuticals XFOR|Nilai perusahaan marang bathi resik ACET|CELU - Rasio rega marang bathi|INmune Bio Inc (INMB) - Koefisien rega marang bathi|BRNS: Pangali P/E|Kezar Life Sciences Inc (KZR) - Pangali P/E|Koefisien rega marang bathi SABS|AKTX: Nilai perusahaan marang bathi resik|Pangali P/E ENLV|Periode bali modal bisnis q32bio.com|Rasio rega marang bathi GeoVax Labs Inc GOVX|EDSA - Koefisien rega marang bathi|IBIO - Rasio rega marang bathi|Carisma Therapeutics (CARM) - Koefisien rega marang bathi|XTLB (XTL Biopharmaceuticals Ltd.) - Koefisien rega marang bathi|Bolt Biotherapeutics, Inc. (BOLT) - Pangali P/E|Rasio rega marang bathi HCW Biologics, Inc.|Pangali rega marang bathi APVO (Aptevo)|Pangali P/E AIM|ADTX - Kapitalisasi marang bathi|Pangali P/E GRI (GRI Bio)|Periode bali modal bisnis XORTX Therapeutics Inc (XRTX)|HIND - Rasio rega marang bathi|Revelation Biosciences Corp (REVB) - Koefisien rega marang bathi|INDP: Pangali P/E|scinai.com (SCNI) - Pangali P/E|CALI (CalciMedica Inc) - Pangali P/E|AFMD - Rasio kapitalisasi marang bathi resik|Pangali P/E ALLK|HOOK - Kapitalisasi marang bathi|Rasio rega marang bathi IGM Biosciences IGMS|ITOS: Pangali rega marang bathi|Ocean Biomedical - Pangali P/E|Kapitalisasi marang bathi TC BioPharm (Holdings) Plc|THRD: Pangali P/E
